Company intelligence / Profile preview

Mononuclear Therapeutics Limited

Shatin, New Territories, Hong Kong SAR China

Ownership: Private
Development stage: Phase 1

Overview

Mononuclear Therapeutics is developing umbilical cord blood mononuclear cell therapies for neurological conditions such as spinal cord injury, stroke, and age-related macular degeneration. Their programs are in preclinical stages, with collaborations for animal studies and a focus on building internationally accredited cell banks[1][2][4].

Therapeutic areas: OphthalmologyNeurology
Modalities: Cell therapy (umbilical cord blood mononuclear cells)
Industry: Biotech

Drug pipeline

2 assets

autologous cord blood mononuclear cells

1 more asset in the full pipeline.

Request access →

Partnerships

Hong Kong Science and Technology Parks Corporation (HKSTP)[3]Chinese University of Hong Kong[3]

Beyond the preview

Go deeper on Mononuclear Therapeutics Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mononuclear Therapeutics Limited.

Explore the full profile